AstraZeneca gets import & marketing approval for Durvalumab in India
Category: #health  By Saipriya Iyer  Date: 2018-06-24
  • share
  • Twitter
  • Facebook
  • LinkedIn

AstraZeneca gets import & marketing approval for Durvalumab in India

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab cite reports. Authentic sources claim that the drug is used to treat patients affected due to advanced & unresectable non-small cell lung cancer (NSCLC) and metastatic urothelial carcinoma.

Durvalumab, also known by the name of ImfinziTM is a patented drug of AstraZeneca Global and is a part of a new class of immunotherapy medicines also referred as checkpoint inhibitors

Business Standard has reported that Durvalumab had received the status of ‘breakthrough therapy” from the U.S. Food & Drug Agency on 31st July 2017. Reports claim that in February this year, the U.S. regulatory body had approved the drug for treating unresectable stage III non-small cell lung cancer.

Reportedly, the market price of the firm’s stocks increased by 5% and hit INR 1,416 in the early morning trade after AstraZeneca announced the approval of its drug from the Indian drug regulator. AstraZeneca Pharma has also emphasized that the approval of Durvalumab has facilitated the firm to introduce the drug in the country, subject to related statutory approvals & licenses.

Gagan Singh, MD of AstraZeneca Pharma India, has stated that receiving the import & market permission for Durvalumab to treat both NSCLC in its third stage and metastatic urothelial carcinoma is a landmark for patients having limited cancer treatment alternatives.

He further added that the country houses nearly one-third of the patient population affected from stage three NSCLC and amidst this grim scenario, AstraZeneca is happy to bring forth the first immunotherapy for NSCLC patients.



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

CTI-Medidata partner to adopt Remote Source Review in clinical trials
CTI-Medidata partner to adopt Remote Source Review in clinical trials
By Saipriya Iyer

CTI Clinical Trial and Consulting Services will reportedly adopt Remote Source Review of Medidata. Medidata is the end-to-end solutions provider to support the clinical trials. This contract research organization will ...

NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
NIMS begins subject enrollment for Phase 1 trial of COVID-19 vaccine
By Saipriya Iyer

Nizam’s Institute of Medical Science (NIMS) has recently commenced the enrollment of subjects for its Phase 1 clinical trials of the COVID-19 vaccine. It is the 1st indigenous coronavirus vaccine candidate develo...

Walmart to compete Amazon Prime with new subscription service, Walmart
Walmart to compete Amazon Prime with new subscription service, Walmart
By Saipriya Iyer

U.S retail giant, Walmart Inc. has recently joined the race against Amazon with its latest subscription service, Walmart+. Similar to Amazon Prime, the new subscription service will endow Walmart customers wi...